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Summary Objective: To evaluate the methodology and cumulative evidence
presented in systematic reviews of clinical trials comparing low-molecular-weight
heparin (LMWH) with unfractionated heparin (UFH) for the treatment of venous
thromboembolism.
Methods: We reviewed all systematic reviews of clinical trials published until
March 2002. Fourteen systematic literature reviews were published between 1994
and 2000. Deficiencies in methodological quality were common, particularly in the
description of search strategies, assessment of clinical trial quality, and methods
used to combine results.
Results: Results of reviews indicate that LMWH is superior to UFH for the
treatment of venous thromboembolism, particularly in reducing mortality. Patients
with isolated deep venous thrombosis or deep venous thrombosis with concomitant
pulmonary embolism seemed to have similar benefit. However, the benefits of LMWH
over UFH were smaller in magnitude in reviews that included more recent clinical
trials.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Venous thromboembolism (VTE), defined as deep
venous thrombosis (DVT), pulmonary embolism
(PE), or both, is a common cause of morbidity and
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mortality. The annual incidence of VTE is estimated
to be about 100 per 100,000 population, with a 1-
month case-fatality rate as high as 32%.1 Tradition-
ally, the cornerstone of initial treatment for VTE
has been anticoagulation with intravenous unfrac-
tionated heparin (UFH) until a therapeutic level of
oral anticoagulation with warfarin is achieved.
However, because UFH has variable clinical effects,
its use necessitates frequent blood tests and dosage
adjustments to maintain safe and effective levels
of anticoagulation. By contrast, the anticoagulation
effects of low-molecular-weight heparins (LMWHs)
are more predictable, eliminating the need for
routine laboratory monitoring.2 For this reason, the
relative safety and efficacy of LMWHs compared
with UFH has been intensively examined in a
number of clinical trials.2
Systematic reviews of published literature and
the quantitative pooling of individual trial results
are often used to summarize evidence across
individual clinical trials. However, the relative
benefits and risks of treatments may evolve over
time, as results of newer trials revise the
cumulative body of evidence reported in previous
systematic reviews.3–6 Also, there is growing
awareness that differences in study methodology
between various systematic reviews, including
criteria used to select component clinical
trials, can lead to qualitative and quantitative
differences in the conclusions of these reviews.7–9
To date, no studies have evaluated the cumulative
body of evidence provided by systematic reviews of
literature related to LMWH and UFH for the
treatment of VTE. The objectives of this study
were to evaluate the methodology and to synthe-
size the cumulative body of evidence presented in
these reviews.
Methods
Literature search
Electronic literature sources were used to identify
all reviews from 1966 to March 2002 that were
relevant to the research question. Several litera-
ture-indexing systems were searched to identify
articles relevant to this study. These included
MEDLINEs, MICROMEDEXs, the Cochrane Con-
trolled Trials Register, and the Cochrane Database
of Systematic Reviews. The following search terms
were combined in a series of OR statements to
maximize sensitivity: quantitative, methodology,
systematic, meta-analysis, metaanalysis, meta
analysis, meta-analyses, review, clinical confer-
ence, consensus development conference, guide-
line, practice guideline, venous thrombosis, deep
venous thrombosis, DVT, venous thromboembolism,
pulmonary embolism, PE, low molecular weight
heparin, LMWH, enoxaparin, logiparin, tinzaparin,
certoparin, logiparin, reviparin, nadroparin, san-
doparin, parnaparin, fraxoparine, dalteparin, te-
delparin, CY222, Lovenox, Fragmin, Clivarin,
Embolex, Innohep, Fluxum, Clexane, and Tedral.
To ensure a comprehensive literature search and
identification of all relevant articles, we examined
reference lists from articles identified through
electronic searching, and reviewed the tables of
contents of issues published between October 2001
and March 2002 of commonly cited clinical journals
relevant to the management of VTE, including:
American Journal of Respiratory and Critical Care
Medicine, Annals of Internal Medicine, Archives of
Internal Medicine, Arteriosclerosis, Thrombosis
and Vascular Biology, Blood, British Journal of
Haemotology, British Medical Journal, Chest, Cir-
culation, Circulation Research, Journal of the
American Medical Association, Journal of Compu-
ter Assisted Tomography, Journal of Nuclear Med-
icine, Lancet, Magnetic Resonance Medicine, New
England Journal of Medicine, Radiology, Seminars
in Nuclear Medicine, Thorax, and Thrombosis and
Haemostasis. Finally, we queried an external panel
of experts in the field for relevant articles missing
from the final list. A more detailed description of
the methods is published in a report prepared for
the US Agency for Healthcare Research and Quality,
publication number 03-E016.
Article selection
Two authors independently reviewed the abstracts
identified by the search to exclude those that did
not meet the eligibility criteria. Systematic reviews
were eligible for inclusion if they reported clinical
outcomes of randomized trials comparing the
relative benefits of LMWH with UFH for the
treatment of VTE, and if they selected articles
based on pre-specified inclusion criteria.8 An
article was included if one or both paired reviewers
believed it was eligible, but excluded if both
agreed it was ineligible.
Data extraction and quality evaluation
We developed and pilot-tested article-review forms
to standardize the data extraction process. These
forms were completed independently by paired
reviewers, recording the following specific ele-
ments of eligible systematic reviews: (1) study
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methodology (aims of the systematic review, search
strategy, eligibility criteria, quality assessment of
component trials, methods used to combine results
across component trials) and (2) results (number
and dates of publication of component trials,
LMWHs included, summary treatment effects, and
authors’ conclusions). Each reviewer was also asked
to assess the methodological quality of each
systematic review using items that were selected
from previous publications.10–15 These items cov-
ered five domains: (1) search methods (four
criteria, total 8 points: description of search
methods [2 points], comprehensiveness of search
methods [2 points], reproducibility of review
methods [2 points], assessment of publication bias
[2 points]); (2) eligibility criteria for component
trials (three criteria, total 6 points: description of
inclusion criteria [2 points], appropriateness of
inclusion criteria [2 points], discussion of differ-
ences in study designs across component trials [2
points]); (3) study quality assessment of the
component trials (two criteria [total 4 points],
description of quality assessment [2 points], appro-
priateness of quality assessment [2 points]); (4)
combining results across component trials (two
criteria [total 4 points]: description of methods [2
points], an assessment of heterogeneity of results
across component trials [2 points]), and (5) degree
to which aims and conclusions were supported by
the evidence (two criteria [total 4 points], primary
question clearly stated [2 points], conclusions
supported by data, analyses, or both [2 points]).
Reviewers independently recorded a score for each
item as 0 (criteria not satisfied), 1 (criteria partially
satisfied) or 2 (criteria fully satisfied). Disagree-
ments between reviewers were resolved by con-
sensus. Quality scores for each domain were
calculated by dividing the actual score by the total
possible score (possible range 0–100%), with higher
scores indicating better methodological quality. We
elected to report a mean score for each of the five
domains of methodological quality (% of total
points), rather than one overall quality score for
each review, as overall scores are less informative
and may divert attention from key sources of
heterogeneity between studies.
Analyses
Descriptive statistics (means, range, proportions)
were used where appropriate to summarize review
characteristics. There was substantial variation
between systematic reviews in which, if any,
summary treatment effect(s) were reported (none,
odds ratio [OR], number needed to treat [NNT],
relative risk [RR], relative risk reduction [RRR],
absolute risk reduction [ARR]), precluding quanti-
tative comparison of the pooled summary treat-
ment effect across all systematic reviews. To
summarize the available evidence, we calculated
the ARR (proportion with outcomes in patients
assigned LMWH minus proportion with outcomes
assigned UFH) in systematic reviews that reported
the proportion of patients with clinical outcomes
according to treatment assignment averaged across
component trials. To evaluate whether differences
in component clinical trials included in the
systematic reviews contributed to the variability
in results across reviews, we examined the rela-
tionships of study population (isolated DVT vs. VTE)
and publication year of the most recent component
trial in each systematic review with the ARR. A two-
tailed P value less than 0.05 reported by systematic
reviews was used to define statistically significant
differences in outcomes between patients treated
with LMWH compared with UFH.
Results
The literature search and subsequent abstract
review identified 31 reviews, of which 17 were
excluded after examining the full text: nine did not
include a systematic review, four did not apply to
the treatment of VTE, three were duplicates
published with different citations and two did not
discuss clinical outcomes. The number of exclusions
exceeded the number of articles reviewed because
articles could be excluded for more than one
reason. After article review, 14 systematic reviews
remained eligible (Table 1).16–29 Eleven different
LMWHs were compared with UFH in the clinical
trials (fragmin, CY222, fraxiparin, logiparin, enox-
aparin [clexane], dalteparin, parnaparin [OP2123],
certoparin, nadroparin, tinzaparin and reviparin).
One review focused exclusively on trials evaluating
dalteparin,18 but all other systematic reviews
included trials evaluating different LMWHs. The
LMWHs most often included were enoxaparin (13
reviews), dalteparin (11 reviews), nadroparin (10
reviews), tinzaparin (nine reviews), reviparin (eight
reviews), and CY222 (eight reviews). No clinical
trials directly compared the safety and efficacy of
the various LMWHs.
Characteristics of systematic reviews
Study population
In nine systematic reviews, the objective was to
evaluate the efficacy of LMWH compared with UFH
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Table 1 Characteristics of systematic reviews.
Reference Last trialn Trialsw Patientsw LMWH used in trialsz Systematic review quality scores Aims and conclusionsww
Searchy EligibilityO Study qualityz Combining resultsnn
Green et al.16 1993 9 1308 1, 2, 3, 4, 5 0 33 0 0 75
Hirsh et al.25 1993 13 1723 1, 2, 3, 4, 5 38 83 75 75 100
Lensing et al.26 1994 10 1512 1, 2, 3, 4, 5 50 67 0 100 100
Leizorovicz27 1996 20 3333 2, 5, 6, 7, 8, 9, 10 12 17 0 75 75
Howard18 1995 8 863 6 38 33 0 25 100
Brewer28zz 1997 6 2986 5, 6, 9, 10, 11 38 67 0 50 100
Hettiarachchi et al.17 1998 13 4509 2, 5, 6, 9, 10, 11 50 83 0 75 100
Hunt19 1997 10 Not reported 5, 6, 9, 10, 11 25 0 0 0 75
Martineau and Tawil20 1996 13 2825 5, 6, 9, 10 25 83 0 0 100
Gould et al.21 1997 11 3674 5, 6, 9, 10, 11 88 100 75 100 100
Dolovich et al.22 1997 13 4447 5, 6, 9, 10, 11 50 67 50 100 100
Rocha et al.23 1997 21 4472 2, 4, 5, 6, 7, 8, 9, 11 38 83 0 100 75
van den Belt et al.24 1997 14 4754 2, 5, 6, 9, 10, 11 62 100 75 100 100
van der Heijden et al.29 2000 16 6055 2, 5, 6, 8, 9, 10, 11 25 67 0 100 100
LMWH, low molecular weight heparin.
nYear of publication of most recent component trial included in systematic review.
wNumber of component trials and total number of participants included in systematic review.
zLMWH: 1¼ fragmin, 2¼CY222, 3¼ fraxiparin, 4¼ logiparin, 5¼ enoxaparin (clexane), 6¼dalteparin, 7¼parnaparin (OP2123), 8¼ certoparin, 9¼ nadroparin, 10¼ tinzaparin,
11¼ reviparin.
ySearch: percentage score based on a total maximum score of 8 points. This included description of search methods (2 points), comprehensiveness of search methods (2 points),
reproducibility of review methods (2 points) and assessment of publication bias (2 points).
OEligibility: percentage score based on a total maximum score of 6 points. This included description of study inclusion criteria (2 points), appropriateness of study inclusion criteria (2
points) and discussion of differences in study designs in component trials (2 points).
zStudy quality: percentage score based on a total maximum score of 4 points. This included description of quality assessment of component trials (2 points) and appropriateness of
quality assessment (2 points).
nnCombining results: percentage score based on a total maximum score of 4 points. This included description of methods used to combine study results (2 points) and an assessment of
heterogeneity across component trials (2 points).
wwAims and conclusions: percentage score based on a total maximum score of 4 points. This included whether the question to be addressed by the review was clearly stated (2 points),
and whether the conclusions reached by the review were supported by data, analyses, or both (2 points).
zzReview examined three meta-analyses and six randomized clinical trials. Only the data from randomized clinical trials are presented here.
Lo
w
-m
o
le
cu
lar-w
e
igh
t
h
e
p
arin
fo
r
ve
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
379
in patients with VTE,17–19,22–25,28,29 whereas five
limited their review to trials that enrolled patients
with isolated DVT.16,20,21,26,27 No systematic re-
views focused exclusively on clinical trials compar-
ing LMWH with UFH for patients with PE.
Year of publication of component clinical trials
The systematic reviews examined randomized
clinical trials published from 1993–2000 (Table 1).
The number and publication years of component
trials included within reviews varied substantially
(mean 13, range 6–21), even when reviews were
published in the same year. For example, the four
most recent reviews were published in 2000 and
included between 13 and 21 trials22–24,29 Only one29
of these four reviews included the most recently
published clinical trial comparing LMWH with
UFH.30
Methodological quality
The methodological quality varied substantially
between the systematic reviews (Table 1), with
more recent reviews frequently having higher
quality scores. Most reviews adequately described
the study aims, eligibility criteria for component
clinical trials, and provided conclusions consistent
with the results of their analyses. However, the
search methods used to identify clinical trials were
often inadequate, incompletely described, or both.
Only one review evaluated the possibility of an
incomplete literature search,21 concluding that
small negative trials (outcomes similar with LMWH
or UFH) may not have been published or identified
by their review. Only four reviews included a formal
assessment of the quality of the component
trials.21,22,24,25 Ten out of 14 reviews quantitatively
pooled results,16,17,21–27,29 but only six of these
provided an adequate description of the methods
and assessed the possibility of heterogeneity of
results across component trials.21–24,26,29
Clinical outcomes reported in systematic
reviews
The clinical outcomes most consistently reported
were recurrence of symptomatic VTE, major
bleeding and all-cause mortality (Table 2). Fewer
reviews evaluated thrombus exten-
sion,16,20,23,24,26,27 minor bleeding,21,22,25 and
thrombocytopenia.21,22,28 Most reviews reported
recurrence of VTE and mortality data at 3 or 6
months after VTE diagnosis, although two reviews
also examined differences in outcomes at several
earlier times, for example days 1–15, 16–90, and
1–9025 or during the period of heparin use.24
Reviews reported bleeding during the initial period
of concomitant heparin treatment (LMWH or UFH),
before use of oral anticoagulation alone.
Four systematic reviews published in 199718 and
199819,20,28 were descriptive and did not quantita-
tively pool results. The remaining 10 reviews
provided measures of treatment effects after
quantitative pooling of data from clinical
trials.16,17,21–27,29 Two reviews reported pooled
ORs only.23,29 Eight reviews reported various com-
binations of two or more pooled summary measures
(ARR, NNT, RRs, RRRs, ORs, and event rates
according to treatment assignment).16,17,21,22,24–27
Recurrence of symptomatic venous
thromboembolism
The range of recurrence rates of VTE reported in
the systematic reviews was from 2.4–4.6% com-
pared with 4.5–7.4% (LMWH vs. UFH, respectively).
Of the 10 reviews that quantitatively pooled results
across trials, four reported that LMWH significantly
reduced the risk of recurrent thrombosis,16,25,26,29
and six indicated a trend toward a protective effect
with LMWH.17,21–24,27 Results of the descriptive
reviews were discordant, indicating that LMWH was
more effective,19 that there was no difference
between LMWH and UFH20,28 or that data were
insufficient to answer the question.18
Mortality
The range of mortality rates was 3.3–6.4% com-
pared with 5.4–8.0% (LMWH vs. UFH, respectively).
Eleven of the 14 systematic reviews examined
differences in rates of all-cause mortality in
patients according to treatment assignment.17,20–
29 Nine reviews quantitatively pooled results for
this outcome, and all indicated that LMWH sig-
nificantly reduced mortality during the 3–6 months
of follow-up compared with UFH.17,21–27,29 The two
descriptive reviews suggested that mortality was no
lower with LMWH than with UFH.20,28
Major bleeding
The range of major bleeding rates was 0.9–2.2%
compared with 1.9–4.7% (LMWH vs. UFH, respec-
tively). In eight out of the 10 reviews that
quantitatively pooled the data, patients treated
with LMWH had significantly fewer episodes of
major bleeding than those treated with
UFH.16,17,23–27,29 One review reported a significant
benefit with LMWH when using a fixed-effects
model (but only a trend towards benefit using a
random-effects model),21 and another review
indicated a non-significant trend toward less
bleeding with LMWH than with UFH.22 As with
recurrence of VTE, the descriptive reviews either
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indicated that LMWH was more effective,19 that
there was a lack of difference between LMWH and
UFH20,28 or that there were insufficient data.18
Relationship to review characteristics
The lack of uniformity in the type of pooled
estimate of treatment effect reported by the
various systematic reviews precluded comparing
the same summary measure across all reviews.
Event rates by treatment assignment (averaged
across component trials within each review) were
the most commonly reported summary measure,
reported in eight out of 10 reviews that quantita-
tively pooled trial results.16,17,21,22,24–27 In these
reviews, we calculated the ARR (proportion with
outcomes in patients assigned LMWH minus propor-
tion with outcomes assigned UFH) based on average
event rate across the component trials by treat-
ment assignment for the three outcomes most
commonly reported. These were symptomatic VTE
recurrence within 3–6 months’ follow-up); mortal-
ity within 3–6 months’ follow-up and major bleed-
ing during initial heparin therapy. We examined
graphically the relationship of these ARRs to the
study population (Fig. 1) and year of publication of
the most recent component trial (Fig. 2).
There was no consistent relationship between
ARRs in these clinical outcomes and study popula-
tion (isolated DVT vs. VTE, Fig. 1). However,
smaller and non-significant ARR were more often
reported in reviews that included more recently
published clinical trials (Fig. 2). All five reviews
that included clinical trials published since 1996
reported no significant differences in recurrence
rates of VTE between LMWH and UFH. The risk
reduction for mortality with LMWH was diminished,
but remained significant, in reviews that in-
cluded more recently published clinical trials.
Reductions in major bleeding rates with LMWH
were smaller and less consistently significant in
reviews that included more recently published
trials.16,17,21,22,24–27
Two recent reviews examined clinical trials of
patients with VTE published in 199723 and 2000,29
and quantitatively pooled effect sizes across trials,
but were not included in these figures because they
did not report event rates by treatment assign-
ment. One review29 reported a significant reduc-
tion in VTE recurrence (OR 0.66, 95% confidence
interval (CI) 0.51–0.86), whereas the other23
reported a trend in favour of LMWH (OR 0.78, 95%
CI 0.59–1.04). Both, however, reported significant
reductions in mortality (OR 0.68, 95% CI 0.53–
0.8829; OR 0.68, 95% CI 0.50–0.9123) and major
bleeding (OR 0.56, 95% CI 0.38–0.8329; OR 0.65 95%
CI 0.43–0.9823) with LMWH.
Discussion
To our knowledge, this is the first study to evaluate
the cumulative body of evidence presented by
systematic reviews of clinical trials comparing
LMWH with UFH for VTE. From 1994 to 2000, 14
systematic reviews were published examining clin-
ical trials comparing LMWH with UFH for the
treatment of isolated DVT or VTE. The methodolo-
gical quality of these systematic reviews varied
substantially, with fewer deficiencies noted in more
recent reviews. Overall, these reports suggest that
LMWH is at least as effective as UFH for reducing
risk of symptomatic VTE recurrence, possibly
superior to UFH for reducing risk of major bleeding,
and superior to UFH for reducing mortality. The
relative benefit of LMWH over UFH was similar in
patients with isolated DVT or VTE. The magnitude
of benefit, however, was smaller in reviews that
included more recently published clinical trials.
Deficiencies in methodological quality were most
evident in the description of search strategies,
assessment of clinical trial quality and methods
used to combine results across trials. Systematic
reviews are expected to use a well-defined and
comprehensive approach in identifying component
trials. However, there was only modest overlap in
component trials selected for review across stu-
dies. This finding could not be explained by
differences in the review’s year of publication or
study population (isolated DVT or VTE), suggesting
that systematic reviews were frequently incom-
plete. Only one systematic review formally as-
sessed the adequacy of their search strategy,
concluding that small negative trials may not have
been published (i.e. publication bias) or identified
by their review.21 Because weakness in the study
design of component trials (e.g. inadequate con-
cealment of treatment allocation) can bias esti-
mates of treatment effect, many experts
recommend assessing methodological quality when
summarizing results across clinical trials.13,31,32
However, the quality of clinical trials was formally
assessed in only four systematic reviews (including
two of four reviews published in 2000).21,22,24,25 In
the presence of heterogeneous results, quantita-
tively combining results across trials and reporting
a single pooled estimate can be misleading, leading
to an under- or over-estimate of treatment
effect.33,34 However, of the 10 reviews that
quantitatively pooled results,16,17,21–27,29 only six
(mostly recent) reviews21–24,26,29 adequately de-
scribed their methods and assessed the possibility
of heterogeneity across component trials. These
various weaknesses highlight the importance of
recent efforts to improve the quality of reporting in
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Table 2 Study population and results of systematic reviews.
Reference Patient
population
Recurrence of symptomatic
VTE (LMWH vs. UFH)
Thrombus extension(LMWH
vs. UFH)
Major bleeding during
treatment (LMWH vs. UFH)
All deaths (LMWH vs. UFH) Comments
Green et al.16 DVT During months 3–6: incidence
2.7% vs. 7.4%; RRR 63%
[CI 30–80%]; 8 trials
64% vs. 50% had thrombus
size reduction; 6% vs. 12%
had increase in size;
Po0:001; 8 trials
0.9% vs. 3.2%; RRR 71%
[CI 33–88%]; 8 trials
Hirsh et al.25 VTE Days 1–15: incidence 0.8% vs.
2.4%; RRR 68%; P ¼ 0:02; 6
trials
2.2% vs. 4.7%; RRR 66%;
P ¼ 0:04; 10 trials
0.6% vs. 1%; days 1–15: RRR
39%; P ¼ 0:3; 12 trials
Days 16–90: incidence 1.6% vs.
2% RRR 26%; P ¼ 0:8; 6 trials
2.5% vs. 4.5%; days 16–90:
RRR 52%; P ¼ 0:03; 12 trials
Days 1–90: incidence 2.4% vs.
4.5%; RRR 50%; P ¼ 0:02; 6
trials
3.3% vs. 5.9%; days 1–90:
RRR 49%, P ¼ 0:01; 12 trials
Lensing
et al.26
DVT Incidence 3.1% vs. 6.6%; RRR
53% [CI 18–73%]; 5 trials
63% vs. 52% had reduction in
thrombus size; 6% vs. 12%
had increase in thrombus
size; Po0:001; 9 trials
0.9% vs. 3.2%; RRR 68%
[CI 31–85%]; 10 trials
3.9% vs. 7.1%; RRR 47%
[CI 10–69%]; 5 trials
Leizorovicz27 DVT Incidence 3.8% vs. 5.2%; OR
0.77 [CI 0.55–1.08]; 20 trials
6.0% vs. 9.5%; OR 0.65
[CI 0.44–0.96]; 12 trials
1.5% vs. 3.1%; OR 0.59
[CI 0.35–0.98]; 20 trials
3.7% vs. 5.4%; OR 0.70
[CI 0.50–0.98]; 20 trials
Howard18 VTE Descriptive studyw. Authors
concluded that dalteparin
may be as effective as UFH in
treatment for DVT and PE;
more data needed
Brewer28 VTE Descriptive studyw. Authors
concluded that LMWH is as
effective and safe as UFH.
Thrombocytopenia less
frequent with LMWH.
Osteoporosis may be less
common with LMWH
Hettiarachchi
et al.17
VTE Incidence 3.8% vs. 4.8%; OR
0.77 [CI 0.56–1.04]; 10 trials
1.3% vs. 2.2%; OR 0.60
[CI 0.38–0.95]; 13 trials
4.8% vs. 6.5%; OR 0.72
[CI 0.55–0.96]; 9 trials
Hunt19 VTE Descriptive studyw. Authors
concluded that LMWH is
cheaper, better tolerated,
potentially more effective
than UFH for DVT. Insufficient
data regarding PE
3
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Table 2 (continued)
Reference Patient
population
Recurrence of symptomatic
VTE (LMWH vs. UFH)
Thrombus extension(LMWH
vs. UFH)
Major bleeding during
treatment (LMWH vs. UFH)
All deaths (LMWH vs. UFH) Comments
Martineau
and Tawil20
DVT Descriptive studyw. Authors
concluded LMWH as safe and
effective as UFH
Gould et al.21 DVT Incidence 4.6% vs. 5.4%; OR
0.85 [CI 0.63–1.14]; ARR 0.88%
[CI 0.48–2.24%]; NNT 114; 11
trials
Random-effects model: OR
0.71 [CI 0.40–1.27]; 11
trials
5.0% vs. 6.8%; OR 0.71
[CI 0.53–0.94]; ARR 1.65%
[CI 0.36–2.94], NNT 61; 11
trials
1.1% vs. 1.9%; fixed-effects
model OR 0.57 [CI 0.33–
0.99]; ARR 0.61% [CI
0.04%–1.26%]; NNT 164;
11 trials
Dolovich
et al.22
VTE Incidence 4.3% vs. 5.1%; RR
0.85 [CI 0.65–1.12]; 13 trials
1.5% vs. 2.6%; RR 0.63
[CI 0.37–1.05]; 13 trials
4.9% vs. 6.5%; RR 0.76
[CI 0.59–0.98]; 10 trials
Rocha et al.23 VTE OR 0.78 [CI 0.59–1.04]; 13
trials
OR for extension 0.73
[CI 0.59–0.90]; 12 trials
OR 0.65 [CI 0.43–0.98]; 8
trials
OR 0.68 [CI 0.50–0.91]; 9
trials
van den Belt
et al.24
VTE Initial treatment: incidence
1.8% vs. 2.6%; OR 0.70
[CI 0.46–1.06]; 11 trials
60% vs. 54% had reduction in
thrombus size; OR 0.77
[CI 0.61–0.97] for better
venographic outcome; 8
trials
1.3% vs. 2.1%; OR 0.60
[CI 0.39–0.93]; 14 trials
6.4% vs. 8.0%; OR 0.78
[CI 0.62–0.99]; 11 trials
3 months: incidence 3.8% vs.
5.1%; OR 0.75 [CI 0.46–1.01];
9 trials
6 months: OR 0.76
[CI 0.44–1.30]; 3 trials
End of follow-up: incidence
4.3% vs. 5.6%; OR 0.76
[CI 0.57–1.01]; 11 trials
van der
Heijden
et al.29
VTE OR 0.66 [CI 0.51–0.86]; 13
trials
OR 0.56 [CI 0.38–0.83]; 16
trials
OR 0.68 [CI 0.53–0.88]; 12
trials
ARR, absolute risk reduction; CI, 95% confidence interval; DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; NNT, number needed to treat; OR, odds ratio; PE,
pulmonary embolism; RR, relative risk; RRR, relative risk reduction; UFH, unfractionated heparin; VTE, venous thromboembolism.
wNo quantitative pooling of data (descriptive study). Pooled summary effect (LMWH vs. UFH) across component trials.
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systematic reviews.35 The clinical outcomes most
commonly reported by systematic reviews were
symptomatic VTE recurrence (14 out of 14 re-
views), major bleeding (14 out of 14 reviews), and
all-cause mortality (11 out of 14 reviews). Results
from most systematic reviews indicate that mor-
tality and major bleeding were less common with
LMWH compared with UFH, although the evidence
to support improvements in symptomatic VTE
recurrence was less compelling. Also, the magni-
tude of benefit was smaller in reviews that included
more recent clinical trials. For example, reviews
that included trials published in 1997–1998 found
an ARR in mortality and major bleeding of about
1.5% and 1% compared with 3% and 2.5%, respec-
tively, in reviews limited to trials published earlier.
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Figure 2 Year of last component trial: absolute risk
reduction (ARR) by year of publication of most recent
clinical trial included in systematic review, for VTE
recurrence (Fig. 2a), mortality (Fig. 2b) and major
bleeding (Fig. 2c). Symbols denote whether the summary
treatment effect(s) reported in the systematic review
had a P value X0.05 (J) or P value o0.05 (K). The
numbers adjacent to each symbol refer to the reference
number. DVT, deep venous thrombosis; VTE, venous
thromboembolism.
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Figure 1 Study population: absolute risk reduction (ARR)
of LMWH over UFH, by study population; for VTE
recurrence (Fig. 1a), mortality (Fig. 1b) and major
bleeding (Fig. 1c). Symbols denote whether the summary
treatment effect(s) reported in the systematic review
had a P value X0.05 (J) or P value o0.05 (K). The
numbers adjacent to each symbol refer to the reference
number. ARR, absolute risk reduction; DVT, deep venous
thrombosis; VTE, venous thromboembolism.
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Furthermore, although mortality risk reduction
with LMWH remained significant in reviews that
included more recently published trials, reductions
in major bleeding were less consistently significant.
These observations may reflect a smaller effect size
in more recently published clinical trials (e.g. due
to differences in participant clinical characteris-
tics, LMWH preparations), improving methodologi-
cal quality of systematic reviews, or both. Future
research in this area should include formal meta-
regression analyses to identify clinical (e.g. VTE
sub-population) and study design (e.g. specific
LMWH preparation) characteristics associated with
treatment effect.36
Most clinical trials to date (and therefore
systematic reviews as well) have focused on
patients with isolated DVT or VTE (defined as DVT
with or without concomitant PE). Benefits of LMWH
appear similar in both populations. There are
relatively few data, however, in patients selected
on the basis of PE (whether or not they have
concomitant DVT). Only three published trials have
compared LMWH and UFH for the treatment of PE,
including two small pilot studies (fraxiparine vs.
UFH, 101 patients37; fragmin vs. UFH, 60 pa-
tients38) and a large unblinded multicenter trial
(tinzaparin vs. UFH, 612 patients) in patients
without haemodynamically significant PE.39 One
systematic review presented in this report included
all three trials of patients with PE,19 and five
systematic reviews included only the tinzaparin vs.
UFH trial.17,22,24,28,29 Only three systematic reviews
reported summary results separately for patients
with PE, concluding that LMWH was as effective as
UFH in this population.17,18,24
Conclusion
In summary, there is strong evidence that LMWH is
superior to UFH for the treatment of VTE,
particularly in reducing mortality at 3–6 months.
More recent data, however, indicate that the
magnitude of clinical benefit from LMWH is lower
than previously estimated. Additional clinical trials
are needed to examine more rigorously the efficacy
of LMWH for the treatment of PE, but systematic
reviews of existing trials indicate that LMWH is at
least as effective as UFH for these patients as well.
Practice points
* In patients with isolated DVT or DVT with
concomitant PE, LMWH is at least as
effective as UFH for reducing risk of
symptomatic VTE recurrence, possibly
superior to UFH for reducing risk of major
bleeding, and superior to UFH for reducing
mortality.
* The magnitude of benefit with LMWH,
however, appears smaller than previously
reported.
Research directions
* Meta-regression analyses to identify clin-
ical (e.g. VTE sub-population) and study
design (e.g. LMWH preparation) character-
istics related to the magnitude of treat-
ment effect.
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